328 related articles for article (PubMed ID: 32789496)
21. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
[TBL] [Abstract][Full Text] [Related]
22. TP53 rs28934571 polymorphism increases the prognostic risk in hepatocellular carcinoma.
Zhao Y; Zhu C; Chang Q; Yang J; Liu Y; Peng P; Liu C; Cheng R; Chen X; Wu Y; Cheng L; Hu L; Wu X; Yin J
Biomark Med; 2021 Jun; 15(9):615-622. PubMed ID: 34037458
[No Abstract] [Full Text] [Related]
23. Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach.
Ozcan M; Altay O; Lam S; Turkez H; Aksoy Y; Nielsen J; Uhlen M; Boren J; Mardinoglu A
Adv Biosyst; 2020 Jun; 4(6):e2000030. PubMed ID: 32529800
[TBL] [Abstract][Full Text] [Related]
24. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
25. Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma.
Hou S; Chen X; Li M; Huang X; Liao H; Tian B
Aging (Albany NY); 2020 Jul; 12(14):14542-14555. PubMed ID: 32694239
[TBL] [Abstract][Full Text] [Related]
26. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with
Lim HY; Merle P; Weiss KH; Yau T; Ross P; Mazzaferro V; Blanc JF; Ma YT; Yen CJ; Kocsis J; Choo SP; Sukeepaisarnjaroen W; Gérolami R; Dufour JF; Gane EJ; Ryoo BY; Peck-Radosavljevic M; Dao T; Yeo W; Lamlertthon W; Thongsawat S; Teufel M; Roth K; Reis D; Childs BH; Krissel H; Llovet JM
Clin Cancer Res; 2018 Oct; 24(19):4650-4661. PubMed ID: 29950351
[No Abstract] [Full Text] [Related]
27. TMEM166 inhibits cell proliferation, migration and invasion in hepatocellular carcinoma via upregulating TP53.
Yang J; Wang B; Xu Q; Yang Y; Hou L; Yin K; Guo Q; Hua Y; Zhang L; Li Y; Zhang J; Li N
Mol Cell Biochem; 2021 Feb; 476(2):1151-1163. PubMed ID: 33200377
[TBL] [Abstract][Full Text] [Related]
28. Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen.
Yang C; Chen J; Li Y; Huang X; Liu Z; Wang J; Jiang H; Qin W; Lv Y; Wang H; Wang C
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33167027
[TBL] [Abstract][Full Text] [Related]
29. Construction of a genome instability-derived lncRNA-based risk scoring system for the prognosis of hepatocellular carcinoma.
Huang DP; Liao MM; Tong JJ; Yuan WQ; Peng DT; Lai JP; Zeng YH; Qiu YJ; Tong GD
Aging (Albany NY); 2021 Nov; 13(22):24621-24639. PubMed ID: 34799469
[TBL] [Abstract][Full Text] [Related]
30. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma.
Zhou R; Wu K; Su M; Li R
Environ Toxicol Pharmacol; 2019 Aug; 70():103200. PubMed ID: 31158732
[TBL] [Abstract][Full Text] [Related]
31. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.
Liu J; Ma Q; Zhang M; Wang X; Zhang D; Li W; Wang F; Wu E
Eur J Cancer; 2012 Oct; 48(15):2328-38. PubMed ID: 22459764
[TBL] [Abstract][Full Text] [Related]
32. Computational analysis of TP53 vs. CTNNB1 mutations in hepatocellular carcinoma suggests distinct cancer subtypes with differential gene expression profiles and chromatin states.
Biterge Süt B
Comput Biol Chem; 2020 Dec; 89():107404. PubMed ID: 33096424
[TBL] [Abstract][Full Text] [Related]
33. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes.
Bidkhori G; Benfeitas R; Klevstig M; Zhang C; Nielsen J; Uhlen M; Boren J; Mardinoglu A
Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11874-E11883. PubMed ID: 30482855
[TBL] [Abstract][Full Text] [Related]
34. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.
Kong J; Yu G; Si W; Li G; Chai J; Liu Y; Liu J
BMC Cancer; 2022 Feb; 22(1):142. PubMed ID: 35123420
[TBL] [Abstract][Full Text] [Related]
35. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
37. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
Zhang ZY; Hong D; Nam SH; Kim JM; Paik YH; Joh JW; Kwon CH; Park JB; Choi GS; Jang KY; Park CK; Kim SJ
J Hepatol; 2015 Jan; 62(1):121-30. PubMed ID: 25131770
[TBL] [Abstract][Full Text] [Related]
38. The Long-To-Short-Axis Ratio and Multifocality are Associated With TP53 Mutation Status in Surgically Resected Hepatocellular Carcinomas.
Wang X; Chen D; Chen B
Acad Radiol; 2020 Dec; 27(12):1720-1726. PubMed ID: 29941397
[TBL] [Abstract][Full Text] [Related]
39. Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.
Zhang W; He H; Zang M; Wu Q; Zhao H; Lu LL; Ma P; Zheng H; Wang N; Zhang Y; He S; Chen X; Wu Z; Wang X; Cai J; Liu Z; Sun Z; Zeng YX; Qu C; Jiao Y
Gastroenterology; 2017 Jul; 153(1):249-262.e2. PubMed ID: 28363643
[TBL] [Abstract][Full Text] [Related]
40. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response.
Burkhart RA; Ronnekleiv-Kelly SM; Pawlik TM
Surg Oncol; 2017 Jun; 26(2):138-145. PubMed ID: 28577719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
